Omni Bio Pharmaceutical Appoints New CEO

Omni Bio Pharmaceutical, Inc. ("Omni Bio") OMBP -0.03% , a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009. 

Dr. Schneider has recently served as an executive advisor to several large and small pharmaceutical companies, including an extensive role with Pfizer where he was engaged to facilitate strategic planning and decision-making for its early drug development pipeline. He previously held numerous senior-level R&D positions at Wyeth Research, including Executive Vice President & Chief of Operations (2002 to 2009), Senior Vice President, Research Operations & Planning (1992-2002) and Vice President, Worldwide Clinical Operations (1987-1992). 

Dr. Schneider commented, "I am very pleased and excited to be joining Omni Bio at this pivotal point in its drug development and commercialization efforts. I believe its science and IP positions covering new uses of AAT hold great promise for addressing many important areas of unmet medical need. I am also excited to be joined by Dr. Forrest, who brings significant experience, energy and insight to help the further commercialization of Omni Bio's current IP portfolio as well as its drug development efforts for new recombinant versions of AAT." 

Steven Bathgate, interim CEO of Omni Bio, added, "We are thrilled to welcome Drs. Schneider and Forrest to our management team. We believe their collective knowledge and proven track records will significantly enhance Omni Bio's ability to commercialize alternative uses of plasma-derived AAT and chart a solid path forward for its recombinant AAT R&D program." 

About Omni Bio Pharmaceutical, Inc. 

Omni Bio Pharmaceutical ( www.omnibiopharma.com ) is a biopharmaceutical company that is focused on AAT and on developing new recombinant versions of AAT that can be applied to the treatment of a broad range of indications including, for example, Type 1 diabetes, graft rejection, graft versus host disease (GVHD), cardiac conditions and inflammatory bowel diseases. Since its formation, Omni Bio has supported research using animal models and human clinical studies that demonstrate that AAT is a promising agent for ameliorating these conditions. 

Forward-Looking Statements Some of the statements made in this press release are forward-looking statements that reflect management's current views and expectations with respect to future events. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. These risks and uncertainties are based on a number of factors, including but not limited to the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2012. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection

Omni Bio Pharmaceutical, Inc. ("Omni Bio") today announced that U.S. Patent No. 7,850,970, entitled "Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Bacterial Infections," was issued by the United States Patent and Trademark Office (USPTO) on December 14, 2010 (the "New Patent").

The New Patent is part of the technology licensed to Omni Bio through one of its technology license agreements with the University of Colorado Denver (UCD). The New Patent covers inhibition of all forms of Bacillus anthracis infection (commonly known as anthrax) using one or more of four new peptides made up of 10 linked amino acids. These peptides and peptide combinations may act by preventing entry of infective components of anthrax into cells of a subject and therefore prevent anthrax infection in the subject. These peptides are related to Alpha-1 antitrypsin (AAT). Dr. Leland Shapiro, the principal investigator for the studies at UCD, continues to study the role of these peptides in medical disorders.

Dr. Charles A. Dinarello, Acting CEO of Omni Bio, stated, "The issuance of this patent by the USPTO expands our proprietary technology platform and is an important milestone in developing innovative therapies to address potentially large and underserved markets. The focus of this patent demonstrates that AAT and AAT related peptides may have the potential to address a variety of indications, such as the prevention and treatment of anthrax infection, and may open proprietary channels of opportunity for the development of new therapeutics and preventatives in a variety of areas including bacterial infection and biohazards."

Omni Bio Pharmaceutical OTCBB Ticker Symbol Change to OMBP

Omni Bio Pharmaceutical, Inc. (OTCBB: AAFS) recently announced that its common stock trading symbol on the OTCBB will change from AAFS to OMBP concurrence with its previously announced name change to Omni Bio Pharmaceutical, Inc. They symbol change will be effective with the commencement of trading on July 21, 2009.

Omni has been advancing broad-spectrum therapeutics targeting bacterial and viral diseases, biohazards, diabetes, and transplant rejection since February 2006. The Company's core technology is based on novel discoveries made at the University of Colorado involving therapeutic agents already approved for use in humans.

Omni Bio Pharmaceutical, Inc. Completes Name Change and Announces Managerial Appointments and Position Changes

DENVER, CO- Omni Bio Pharmaceutical, Inc. ("OMNI") (OTCBB: AAFS) announces that it has consummated the previously announced name change from Across America Financial Services, Inc. The Company is in process of having a new ticker symbol assigned to more closely reflect its name and will announce the new symbol once it becomes effective.

Omni also announced the appointment of Robert C. Ogden to the positions of Chief Financial Officer, Secretary and Treasurer of both Omni and its wholly owned subsidiary Omni Bio Operating, Inc. Mr. Ogden will be engaged on a part-time basis and is expected to spend approximately 50% of his time on Company related business.

Mr. Ogden brings 20 years of senior financial management experience in both private and public companies. Since 2007, Mr. Ogden has been a financial consultant providing services ranging from interim Vice President of Finance of an IP telephony software company to SEC reporting and accounting assistance for a multi-national, business process outsourcing services company. From 2004 to 2007, Mr. Ogden served as Chief Financial Officer, Treasurer and Secretary of SAN Holdings, Inc., a publicly traded data storage solutions provider and software company, where he was responsible for all administrative and finance functions. From 2000 to 2004, he was a financial consultant, primarily providing financial controller and financial reporting services for both private and public companies in a variety of industries, including software, computer hardware and financial services. From 1997 to 2000, he served as Vice President, Corporate Controller and Chief Accounting Officer for TAVA Technologies, Inc., a publicly held national systems integration and software company. He began his career as a public accountant with PricewaterhouseCoopers. Mr. Ogden holds a B.S. in Commerce from the University of Virginia and is a CPA.

Additionally, both Omni and Omni Bio Operating, Inc. appointed Edward C. Larkin as Chief Operating Officer and Executive Vice President. Mr. Larkin had served as Omni's interim Chief Financial Officer. He has been associated with Omni and its predecessor, Apro Bio Pharmaceutical, Inc., since January 2007.